By: IPP Bureau
Last updated : April 30, 2026 5:38 pm
The medtech firm strengthens its full-stack remote cardiac monitoring platform, achieves 11x revenue growth, and advances its global expansion plans
Monitra Health, the medtech firm behind the upBeat® remote cardiac monitoring platform, has raised a fresh funding round led by IAN Group.
The round saw participation from New Age India Fund, Lavni Ventures, VCMint, Global HealthX (led by Dr. Ravindranath Kancherla), We Founder Circle, Hyderabad Angels, and several prominent angels and healthcare family offices, including Dr. Ramesh Kancherla.
The latest funding round reflects growing investor confidence in Monitra’s clinical depth, intellectual property, and global ambitions. When the company last raised capital in December 2023, it was largely seen as a high-potential player. Two years later, that potential has translated into measurable scale, positioning Monitra not just as a participant but as a category-defining company in remote cardiac monitoring.
The company has significantly expanded both its clinical and commercial footprint. More than 50,000 patients have now been monitored on the upBeat® platform—up from 10,000 at the time of the previous round.
Over the past four years, Monitra has also recorded an 11-fold increase in revenue, driven by disciplined execution and a steadily expanding base of prescribing clinicians. The platform is now used by leading hospital networks and clinicians associated with groups such as Apollo Hospitals, Manipal Hospitals, Aster DM Healthcare, and AIG Hospitals, with a growing presence across Tier 1 to Tier 4 cities in India.
“Our last round was about proving this could work. This one is about proving it can work everywhere. Crossing 50,000 patients, analyzing over 10 billion heartbeats, and growing revenue 11x has moved upBeat® from a promising platform to an indispensable one for a growing number of clinicians. We are grateful to this set of investors for backing that future with us,” said Ravi Bhogu, Founder and CEO of Monitra Health.
“We are truly upBeat about our investment in Monitra Health. It is rare to find a company that combines strong IP, patented technology, cost advantage, and a world-class product built in India for global markets. With growing adoption among leading hospitals and cardiologists, Monitra has demonstrated both innovation and execution. We believe the company has the potential to become a global leader in cardiac monitoring - from India to the world,” said Avinash Kalia.
“We first backed Monitra when the thesis was still being tested. Doubling down today is one of the easier decisions we have made — the clinical footprint has scaled 5x, revenue has grown 11x, the IP has deepened, and the team has stayed remarkably disciplined with capital. Monitra has exactly the kind of deep-tech healthcare solutions India should be exporting to the world,” said Vasu Guruswamy, Co-founder and General Partner at Lavni Ventures.
“As practicing clinicians, we see the diagnostic gap in heart rhythm disorders every day. What Monitra has built is genuinely rare — a device and reporting workflow that is clinician-grade in accuracy, patient-friendly in design, and affordable enough to reach the populations that need it most. Global HealthX is privileged to support this team as they take it worldwide,” added Dr. Ravindranath Kancherla.